Allogeneic hematopoietic stem cell transplantation (HSCT) is the most powerful therapy preventing relapse in patients with adverse cytogenetics acute myeloid leukemia (AML) in first complete remission (CR1). In the absence of a matched related donor, potential alternatives include 10/10, 9/10 HLA-matched unrelated (UD) or haploidentical (Haplo) donors. We analyzed clinical outcomes of patients undergoing T-cell repleted Haplo (n = 74), 10/10 UD (n = 433) and 9/10 UD HSCT (n = 123) from 2007 to 2015, reported to the EBMT Registry. Adverse risk AML was defined according to the 2017 ELN cytogenetic risk classification. The 2-year nonrelapse mortality was 19% for Haplo, 18% for 10/10 UD and 18% for 9/10 UD (P = .9). The relapse incidence was not significantly affected by donor source, with a 2-year incidence of 27% for Haplo HSCT, 39% for 10/10 UD and 37% for 9/10 UD SCT (P = .3). We show comparable probabilities of leukemia-free † A.N. and M.M. equally contributed to this study.
survival (LFS) and overall survival (OS) at 2 years among Haplo HSCT, 10/10 UD SCT and 9/10 UD SCT (53% and 59%, 43% and 50%, 44% and 50%, respectively, P = .5 for both parameters). The type of donor was not significantly associated with either acute or chronic graft-vs.-host disease incidence. Using multivariable Cox model, Haplo HSCT recipients experienced comparable OS and LFS to 10/10 and 9/10 UD. In the present series of adverse cytogenetics AML patients in CR1, Haplo HSCT recipients had comparable outcomes to those of 10/10 and 9/10 UDs, suggesting that all these types of HSCT may be considered a valid option in this high risk population.
| INTRODUCTION
The cytogenetic and molecular profile of leukemic cells at diagnosis is the most important factor affecting outcome and influencing the current risk-stratified therapeutic approach in acute myeloid leukemia (AML). [1] [2] [3] [4] [5] In 2017, the European LeukemiaNet (ELN) updated the recommendations for diagnosis and management of AML patients to provide a standardized system for reporting and correlating cytogenetics with treatment outcomes. 6 Adverse cytogenetic markers have a negative impact on the complete remission rate, on the cumulative incidence of post-treatment relapse and on overall survival in newly diagnosed AML patients.
Several prospective studies have shown that allogeneic hematopoietic stem cell transplantation (HSCT) is the best therapeutic option for adverse cytogenetics AML in first CR (CR1) compared to consolidation chemotherapy or autologous HSCT, which are insufficient to eradicate the leukemic clone in >70% of patients. [7] [8] [9] [10] Unfortunately, a sibling donor is available for only about 30% of patients. With the development of international registries, HLA-matched unrelated donors (UD) are identifiable for many patients, particularly those who are members of certain ethnic groups. 11 Nevertheless, the variability of HLA polymorphisms and the time required for identifying a suitable donor limit the use of UD, especially for patients in whom there is urgency for transplantation. For these patients, haploidentical donors (Haplo) are increasingly utilized. This is due to the emergence of new T-cell repleted platforms combining less toxic conditioning regimens and progress on graft-vs.-host disease (GvHD) prophylaxis, which have allowed lower rates of nonrelapse mortality, GvHD and graft failure, historically the main detrimental factors for this therapeutic approach. [12] [13] [14] Several retrospective reports now show similar outcomes between
Haplo and UD in AML. [15] [16] [17] [18] [19] However, comparative studies able to include sufficient numbers of adverse cytogenetics AML patients in CR1 are scarce. Therefore, this prompted us to compare the outcomes of Haplo to 10/10 and 9/10 UD HSCT in this disease category. 
| METHODS

| Statistical analysis
The primary aim of our study was to assess differences in leukemiafree survival (LFS) of patients who were allocated to Haplo, 10/10 or 9/10 UD HSCT. Secondary endpoints were engraftment, incidence of acute and chronic graft-vs.-host disease (aGvHD and cGvHD, respectively), nonrelapse mortality (NRM), relapse incidence (RI), overall survival (OS) and refined graft-vs.-host-free, relapse-free survival (GRFS).
Clinical endpoints were defined according to EBMT published recommendations. 21 GRFS events have been defined as grades 3-4 acute GVHD, severe chronic GVHD, disease relapse, or death from any cause after HSCT. 22 Actuarial probabilities were determined at 2 years.
Baseline characteristics among groups were compared using the Chi-square test for categorical variables, while the distribution of continuous variables was compared using the Kruskal-Wallis test.
The probabilities of LFS and OS were calculated using the Kaplan-Meier method, and groups were compared by the log-rank test. 23, 24 Cumulative incidences (CI) were estimated for engraftment, GvHD, NRM and relapse to accommodate competing risks, 25 and test of equality across groups were performed according to Gray. 26 Relapse was a competing risk for NRM, death from any cause was a competing risk for engraftment and relapse. Both relapse and death from any causes were competing risks for GvHD. Table 1 .
Recipients of Haplo HSCT were significantly younger compared to UD (median of 49, 53 and 51 years for Haplo, 10/10 UD and 9/10 UD, respectively; P = .03). Moreover, Haplo HSCT were performed in more recent years (P < .001).
Allogeneic HSCT was performed with a median of 5 months from diagnosis for all three donor sources, and after a median of 1 cycle of chemotherapy. There was no difference in time from diagnosis to CR1
and from CR1 to transplantation among the groups.
Adverse cytogenetic abnormalities were not unbalanced with regards to donor type.
Pre-transplant conditioning regimens are detailed in Supporting Information Table 1 .
Haplo HSCT more frequently adopted BM as stem cell source:
38%, 19%, and 17% for Haplo, 10/10 UD and 9/10 UD, respectively (P < .001). GvHD prophylaxis included preferentially in vivo T cell depletion with antithymocyte globulin (ATG) or Campath for UD HSCT and high-dose post-transplant cyclophosphamide (PTCy) for
Haplo HSCT (Table 1) .
| Overall outcomes
The median follow-up for the global population of surviving patients was 23 months (range 1-114). Haplo recipients had a shorter followup compared to 10/10 and 9/10 UD HSCT recipients (15, 23, and 21 months, respectively, P = .08).
The univariate comparison of outcomes is shown in Figure 1 and Supporting Information Table 3 .
Neutrophil engraftment at 30 days was observed in 95% of Haplo recipients, and 96% of both 10/10 and 9/10 UD HSCT recipients (P = .2). Platelet engraftment at 180 days post-HSCT was observed in 85% of patients undergoing Haplo, and 97% after 10/10 UD and 9/10 UD (P < .001).
The 100-day CI of grades II-IV and III-IV aGvHD after Haplo were comparable to 10/10 and 9/10 UD HSCT, being 33 AE11% and 12 AE6%
in Haplo; 30 AE4% and 10 AE3% for 10/10 UD and 34 AE8% and 10 AE4% for 9/10 UD HSCT, respectively (P = .55 and P = .74, respectively).
The 2-year CI of cGvHD of Haplo HSCT was 35 AE12%, which was similar to 10/10 UD (36 AE5%) and 9/10 UD (36 AE9%), P = 0.85. Likewise, no difference was found in the 2-year CI of extensive cGvHD among the donor sources (13 AE7% for Haplo, 16 AE4% for 10/10 UD and 14 AE6% for 9/10 UD, P = .6). The impact of in vivo T cell depletion was mostly evident in 10/10 UD HSCT: in this group, patients who did not receive ATG or Campath experienced a 2-year CI of cGvHD and extensive cGvHD of 49 AE10% and 28 AE9%, respectively, while it was 30 AE5% and 11 AE3% with in vivo T cell depletion (P < .0004 and P < .0005, respectively). This difference was not seen for 9/10 UD HSCT.
The CI of NRM was similar after Haplo and UD HSCT. Causes of death are shown in Supporting Information Table 2 .
For patients who received an Haplo HSCT with PTCy as GvHD prophylaxis, a trend for lower NRM and cGVHD incidence translating into better GRFS and LFS was observed as compared to those who received ATG as shown in Supporting Information 2-year LFS 49 AE20%; P = nonsignificant).
The relapse incidence was not significantly affected by donor source, with a 2-year CI of 27 AE10% for Haplo HSCT, 39 AE5% for 10/10 UD HSCT and 37 AE9% for 9/10 UD HSCT (P = .27).
The overall probabilities of LFS at 2 years were not different between Haplo and UD HSCT: 53 AE12% for Haplo, 43 AE5% for 10/10 UD and 44 AE9% for 9/10 UD HSCT (P = 0.52). OS and GRFS probabilities were comparable as well: 59 AE13% and 39 AE13% in Haplo; 50 AE6% and 30 AE4% in 10/10 UD and 50 AE10% and 32 AE9% in 9/10 UD HSCT, respectively.
In univariate analysis, patients who presented with a MK experienced significantly higher relapse incidence and worse GRFS, LFS and OS, compared to patients who presented with a CK or with other adverse cytogenetic abnormalities (Supporting Information Table 3 ).
We did not find any difference when comparing transplant outcomes of the donor sources within each specific subgroup of cytogenetic abnormalities (Supporting Information Table 5 ).
In multivariate analysis, compared to the Haplo group (reference), the hazard ratios (HR) for GRFS, LFS, OS, RI, NRM, acute and chronic GvHD for 10/10 and 9/10 UD recipients were not significantly different (Tables 2 and 3 ).
The hazards for relapse and survival were significantly influenced by the specific cytogenetic abnormality detected at diagnosis: indeed, HSCT in acute leukemia in remission showed better survival after 10/10 UD, and similar outcomes after Haplo or 9/10 UD HSCT, due to a higher 3-year NRM using Haplo and 9/10 UD (29% for both donor types) compared with 10/10 UD (21%) [18] . In that study, in vivo T-cell depletion with ATG or Campath was more common in the Haplo group compared to PTCy, and that is a potential reason for the discrepancy with the present study. Moreover, the EBMT recently published an analysis with the aim to establish the hierarchy of different allogeneic donor for poor-risk AML patients. 19 In that study, poor-risk AML was defined according to different parameters in addition to adverse cytogenetics, such as: white blood cell count > 100 × .01
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present series, are perhaps at the basis of the partial discordance between our data and the study by Versluis et al. 19 which reported an apparently higher NRM experienced by the Haplo group. In addition, the above mentioned study adopted a different comparator as baseline (siblings) and accounted also for CBU.
Our data raise some considerations regarding the specific setting of adverse karyotype AML patients. In line with the other published series, 29, 30 we report that the presence of a MK identifies a group of patients with very poor prognosis with an expected 2-year LFS of 26% in our study, while AML patients with CK shared the same apparently better 2-year LFS rate as the patients with other adverse cytogenetic abnormalities. This confirms the negative prognostic significance of MK, which holds up even in the context of other cytogenetic abnormalities known to confer a poor prognosis.
However, even after accounting for these cytogenetic subgroups in our multivariable model, we did not detect any difference in the hazards for relapse and LFS among Haplo, 10/10 and 9/10 UD, potentially claiming a similar graft-vs.-leukemia effect exerted across these different donor types.
Moreover, in accordance with the previous literature, 31,32 our data confirm that conditioning intensity could not have a major role on long-term disease control, questioning the importance of MAC in these patients and highlighting the immunotherapeutic action as the large part of the antileukemic efficacy.
Haplo donors could be a safe source, which could allow expansion risk AML and therefore it could be a challenge for a prospective evaluation of the prognostic significance of the three different donor sources, unless very large numbers of patients are included.
The main unresolved problems are still GvHD and relapse, suggesting that most of efforts should be focused to the optimization of post-HSCT complication management and adoption of strategies, such as minimal-residual disease monitoring, early immunosuppression withdrawal, 34, 35 pre-emptive use of immunomodulating agents 36 and post-transplant pharmacologic maintenance therapies or donor lymphocyte infusions to address the concern of disease relapse. 37 The possibility of an earlier referral to Haplo HSCT should be evaluated for its potential to lead higher numbers of patients to transplant before relapse occurrence and before treatment-related toxicities render them ineligible for this life-saving procedure.
